The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
AM23-ST-18-O - AM23-ST-18-O: Potential Role of Intravenous Hemostatic Agents/Adjuncts in Pediatric Trauma: A Review of the Evidence for (or Against) Their Use (Enduring)
This session will focus on the role of anti-fibrinolytics and other hemostatic agents/adjuncts (such as prothrombin concentrates, rFVIIa, fibrinogen concentrates/cryoprecipitate) in controlling bleeding and lowering transfusion needs in pediatric trauma situations. Key animal experimental studies and pediatric/adult clinical studies that support its use in attenuating bleeding in pediatric patients will be presented. In addition, assays that can guide the use of hemostatic agents/adjuncts will be described.
Learning Objectives:
Understand the difference in hemostasis between children and adults.
Describe the evidence for (or against) the use of tranexaminc acid in pediatric trauma and non-trauma bleeding situations.
Describe the evidence for (or against) the use of other hemostatic agents/adjuncts such as prothrombin concentrates (PCC) and other hemostatic agents (eg. rFVIIa, fibrinogen concentrates/cryoprecipitate) in pediatric trauma.
Describe assays that can guide use of these agents/adjuncts in bleeding pediatric patients.
Moderator(s):
Edward
Wong,
MD,
Medical Director, Coagulation,
Quest Diagnostics
Speaker(s):
Marian
Rollins-Raval,
MD,
Professor, Department of Pathology,
University of New Mexico HSC
Phillip
Spinella,
MD,
Professor of Surgery and Critical Care Medicine,
University of Pittsburgh
Disclosures
Marian Rollins-Raval, MD:
Precision Biologic: Grant/Research Support (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing); Siemens: Speaker's Bureau (Ongoing)